{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:53:35Z","timestamp":1767894815884,"version":"3.49.0"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,1,20]],"date-time":"2013-01-20T00:00:00Z","timestamp":1358640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Topical tacrolimus and pimecrolimus are indicated for the treatment of atopic dermatitis, but they have been studied in many off\u2010label uses. We reviewed the English language literature to define their roles in treatment of vitiligo. Double\u2010blind studies show that tacrolimus 0.1% ointment combined with excimer laser is superior to placebo, especially for UV resistant areas, such as bony prominences of the extremities. When used alone, tacrolimus 0.1% ointment is almost as effective as clobetasol propionate 0.05% ointment. Other studies suggest it can also be effective for facial lesions. Double blind studies show that pimecrolimus 1% cream combined with narrow band UVB is superior to placebo, especially for facial lesions. Additional studies would further clarify the role of topical calcineurin inhibitors in vitiligo.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2012.05697.x","type":"journal-article","created":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T03:30:54Z","timestamp":1358739054000},"page":"491-496","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy of topical calcineurin inhibitors in vitiligo"],"prefix":"10.1111","volume":"52","author":[{"given":"Russell","family":"Wong","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Dentistry  Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew N.","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Cutaneous Sciences Department of Medicine University of Alberta Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2010.03.008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.30058.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04002.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.7.927"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.5.581"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-009-0973-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.9.1065"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/pho.2011.3029"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.90949"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03138.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2010.00540.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.02101.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0464"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.03852.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126250"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00774.x"},{"key":"e_1_2_7_18_1","first-page":"158","article-title":"Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series","volume":"71","author":"Tanghetti EA","year":"2003","journal-title":"Cutis"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01632.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.01067.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03128.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.05.036"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2008.00511.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.5.571"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7125.2008.07558.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.037"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065845"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2005.22123.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0781.2003.00005.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06455.x"},{"key":"e_1_2_7_31_1","first-page":"507","article-title":"Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color","volume":"10","author":"Silverberg JI","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.252"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2006.06124.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03228.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802155057"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.00914.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.00926.x"},{"key":"e_1_2_7_38_1","first-page":"55","article-title":"Topical pimecrolimus in the treatment of vitiligo","volume":"17","author":"Boone B","year":"2007","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630601028711"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000099592"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903266761"},{"key":"e_1_2_7_42_1","first-page":"88","article-title":"Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo","volume":"15","author":"Coskun B","year":"2005","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_43_1","first-page":"517","article-title":"Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo","volume":"6","author":"Mayoral FA","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000073099"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02668.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03282.x"},{"key":"e_1_2_7_47_1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1684\/ejd.2009.0779","article-title":"An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo","volume":"19","author":"Stinco G","year":"2009","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-009-0973-3"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.061"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.10.043"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01315.x"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2012.05697.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2012.05697.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:26:40Z","timestamp":1697354800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2012.05697.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,20]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/j.1365-4632.2012.05697.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2012.05697.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,20]]},"assertion":[{"value":"2012-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}